Cargando…
Phase I and pharmacokinetic study of the vascular‐disrupting agent CKD‐516 (NOV120401) in patients with refractory solid tumors
We report a phase I pharmacological study of an oral formulation of CKD‐516, a vascular‐disrupting agent, in patients with refractory solid tumors. Twenty‐seven patients (16 in the dose‐escalation cohort and 11 in the expansion cohort) received a single daily dose (5‐25 mg) of CKD‐516 five days per...
Autores principales: | Kim, Hark Kyun, Kang, Jeong Won, Park, Young‐Whan, Kim, Jung Young, Kim, Minchae, Kim, Soo Jin, Kim, Se‐mi, Ho Ryu, Keun, Yoon, Seonghae, Kim, Yun, Cho, Joo‐Youn, Lee, Keun Seok, Yun, Tak, Kim, Kiwon, Kwak, Mi Hyang, Kim, Tae‐Sung, Chung, Jinsoo, Park, Joong‐Won |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066534/ https://www.ncbi.nlm.nih.gov/pubmed/32162844 http://dx.doi.org/10.1002/prp2.568 |
Ejemplares similares
-
Phase I Study of CKD-516, a Novel Vascular Disrupting Agent, in Patients with Advanced Solid Tumors
por: Oh, Do-Youn, et al.
Publicado: (2016) -
Anti-tumor efficacy of CKD-516 in combination with radiation in xenograft mouse model of lung squamous cell carcinoma
por: Kim, Min-Young, et al.
Publicado: (2020) -
Protective Effect of γ-mangostin Isolated from the Peel of Garcinia mangostana against Glutamate-Induced Cytotoxicity in HT22 Hippocampal Neuronal Cells
por: Baek, Ji Yun, et al.
Publicado: (2021) -
Identification of immune-related mechanisms of cetuximab induced skin toxicity in colorectal cancer patients
por: Park, Jin Hyun, et al.
Publicado: (2022) -
DPP-4 inhibition enhanced renal tubular and myocardial GLP-1 receptor expression decreased in CKD with myocardial infarction
por: Kim, Seung Jung, et al.
Publicado: (2019)